Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FER | P16591 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063202 | 0.83 | KMT2A (0.60) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL457313 | 0.79 | TDP1 (0.56) | KMT2AMEN1GAAMAOAMAOB | |
| SCHEMBL10084821 | 0.79 | KMT2A (0.58) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL98437 | 0.79 | KMT2A (0.58) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL3076655 | 0.79 | KMT2A (0.61) | KMT2AMEN1GAAMAOBALDH1A1 | |
| SCHEMBL11237095 | 0.78 | KMT2A (0.53) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL11237090 | 0.78 | KMT2A (0.53) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL19586520 | 0.78 | KMT2A (0.57) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL458246 | 0.77 | ALDH1A1 (0.49) | KMT2AMEN1GAAMAOAMAOB | |
| SCHEMBL2877863 | 0.76 | ALDH1A1 (0.46) | KMT2AMEN1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015815-A1 | Hydrazide substrate shuts down protein biosynthesis capability in cells that host a metastatic or malignant disease mechanism | DELOACH REUBEN E | 2007-01-18 | — | — | US | claimed |
| EP-0661967-B1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | UNIV VIRGINIA (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0661967-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-12 | — | — | EP | claimed |
| US-5422097-A | Combined antiviral and antimediator treatment of common colds | UNIVERSITY OF VIRGINIA (US) | 1995-06-06 | — | — | US | claimed |
| EP-0661967-A4 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS. | UNIV VIRGINIA (US) | 1994-09-29 | — | — | EP | claimed |
| US-5240694-A | Combined antiviral and antimediator treatment of common colds | UNIVERSITY OF VIRGINIA (US) | 1993-08-31 | — | — | US | claimed |
| WO-1993009764-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-05-27 | — | — | WO | claimed |
| US-12419947-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12102676-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | NAJIT TECHNOLOGIES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240269257-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najít Technologies, Inc. | 2024-08-15 | — | — | US | disclosed |
| EP-3454895-B1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECH INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najít Technologies, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-5422097-A | Combined antiviral and antimediator treatment of common colds | UNIVERSITY OF VIRGINIA (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1994027436-A1 | PRESERVATIVE SYSTEMS WITH ENHANCED ANTIMICROBIAL ACTIVITY | DECICCO BENEDICT T (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0661967-A4 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS. | UNIV VIRGINIA (US) | 1994-09-29 | — | — | EP | disclosed |
| US-5240694-A | Combined antiviral and antimediator treatment of common colds | UNIVERSITY OF VIRGINIA (US) | 1993-08-31 | — | — | US | disclosed |
| WO-1993009764-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-4780477-A | Isatin compositions having anti-ulcer activities | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0205299-A2 | Isatin derivatives, compositions containing the same, and the use thereof for ulcer diseases | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269257-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | KMT2A 1141/4885MEN1 3572/4885GAA 417/4885 |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
| US-12419947-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | KMT2A 1141/4885MEN1 3572/4885GAA 417/4885 |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | KMT2A 1141/4885MEN1 3572/4885GAA 417/4885 |
| US-12102676-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.